Internal medicine

Myocardial infarction

Diabetes mellitus

Post-hoc analysis

Endocrinology

Type 2 diabetes

Dapagliflozin

TIMI

Kidney disease

Thrombolysis

Post hoc

Medicine

Diabetes Care

In patients with moderate to severe albuminuric kidney disease, sodium-glucose cotransporter 2 inhibitors reduce the risk of kidney disease progression. These post hoc analyses assess the effects of dapagliflozin on kidney function decline in patients with type 2 diabetes (T2D), focusing on populations with low kidney risk.

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial